Corporate Symposia
Sunday, September 20
13:30–14:30
Room C3.4–C3.5 · Program #101
Sobi Symposium - Treat the cause, not the consequences: Updates in the management of C3G & primary IC-MPGN
Supported by

Monday, September 21
08:00–09:00
Parkside 1&2 · Program #200
Takeda Corporate Breakfast Symposium on Illuminated Constellations: How Diverse Institutional Experiences Guide Practical CMV Management
Supported by

12:15–13:15
Parkside 1&2 · Program #250
Hansa BioPharma Corporate Lunch Symposium on Transplanting the untransplantable – Idefirix® (imlifidase), a breakthrough innovation for highly sensitised kidney transplantation
Supported by

17:00–17:45
Cockle Bay 2 · Program #298
Expanding the living donor pool in kidney transplantation: Insights from Indian experience
Supported by an educational grant from

Tuesday, September 22
07:00–08:00
Parkside 1&2 · Program #300
Bridge to Life Corporate Breakfast Symposium on Scaling better outcomes: The role of HOPE in contemporary transplant programs
Supported by

12:15–13:15
Parkside 1&2 · Program #350
Astellas Corporate Lunch Symposium on Strengthening the foundation: How consistent management drives durable graft health
Organized by

17:00–18:00
Room C3.3 · Program #398
Corporate Symposium on State-of-the-Art Care for Kidney Transplant Recipients: Implications for the Forthcoming KDIGO Guideline Update
Supported by an independent educational grant from

Wednesday, September 23
07:00–08:00
Parkside 1&2 · Program #400
Biogen Corporate Breakfast Symposium on Microvascular inflammation: A defining characteristic of antibody mediated rejection in kidney transplantation
Supported by
